| Autor: |
Battisti, Nicolò Matteo Luca, True, Victoria, Chaabouni, Narda, Chopra, Neha, Lee, Karla, Shepherd, Scott, Shapira-Rotenberg, Tal, Joshi, Rashi, McGrath, Sophie, Okines, Alicia, Parton, Marina, Turner, Nicholas, Mohammed, Kabir, Allen, Mark, Johnston, Stephen, Ring, Alistair |
| Zdroj: |
Breast Cancer Research & Treatment; Jan2020, Vol. 179 Issue 1, p101-111, 11p |
| Abstrakt: |
Purpose: Pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) for breast cancer predicts the risk of recurrence and increasingly may indicate the need for additional therapy postoperatively. Methods: We identified non-metastatic breast cancer patients receiving NACT during 2013–2017. Patients' and disease characteristics, rates of pCR (ypT0-is ypN0), toxicities, dose delays and reductions, and survival outcomes were recorded. Results: 789 patients had median age of 50 years. 67.8% had stage II disease, 71.1% had grade 3 , and 91.8% had ductal histopathology. 32.8% had estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative, 25.5% had triple-negative (TN), and 38.0% HER2-positive disease. 6.8% received platinum. 48.2% of the HER2-positive patients received trastuzumab and pertuzumab and 51.8% received trastuzumab. Overall pCR rate was 33.5% and differed according to disease subtype, receptor status, grade, histology, and early discontinuation, but not according to age, dose reductions/delays, or year of treatment. The addition of pertuzumab to trastuzumab marginally improved the pCR rates. Survival outcomes were better following pCR. Conclusions: In our analysis, pCR rates are consistent with the published data. Even with contemporary therapies, many patients have residual disease following NACT, suggesting a significant risk of recurrence, and may benefit from additional postoperative systemic therapy. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink